Autonomix Medical, Inc. today announced the release of its latest CEO Corner segment, highlighting the growing scientific and clinical recognition of its nerve-sensing and transvascular denervation platform technology. The company has secured 13 abstract acceptances since last fall, including nine podium presentations and four poster presentations at leading global medical conferences. This peer-reviewed recognition validates the novelty and potential impact of its technology platform for treating complex conditions like pancreatic cancer pain.

President and Chief Executive Officer Brad Hauser outlined the company's progress in the segment, emphasizing the significance of the acceptances at forums such as the Transcatheter Cardiovascular Therapeutics (TCT), Cardiovascular Research Technologies (CRT), Society of Interventional Radiology (SIR), and the American Society of Clinical Oncology Annual Meeting (ASCO). Autonomix received a top Cardiovascular Innovation Award at CRT, further distinguishing its platform technology.

Clinical and Strategic Milestones

The company's real-time nerve sensing and targeted therapy approach is designed to transform treatment paradigms. The recent accolades are expected to support physician adoption, future clinical trials, strategic partnerships, and reimbursement discussions. Autonomix is currently preparing for a planned U.S. clinical study to further evaluate its technology.

Platform Technology Overview

Autonomix's first-in-class platform system features a catheter-based microchip sensing array. The technology aims to detect and differentiate neural signals with greater sensitivity than currently available options. Initial development efforts focus on treating pain associated with pancreatic cancer, a condition with limited reliable solutions. The platform holds potential for broader applications across cardiology, hypertension, and chronic pain management. The technology remains investigational and has not yet been cleared for marketing in the United States.